JP2017522316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522316A5 JP2017522316A5 JP2017502259A JP2017502259A JP2017522316A5 JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5 JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108010028554 LDL Cholesterol Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 208000029078 coronary artery disease Diseases 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229940102223 injectable solution Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 claims 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025371P | 2014-07-16 | 2014-07-16 | |
| US62/025,371 | 2014-07-16 | ||
| US201462043167P | 2014-08-28 | 2014-08-28 | |
| US62/043,167 | 2014-08-28 | ||
| US201462080725P | 2014-11-17 | 2014-11-17 | |
| US62/080,725 | 2014-11-17 | ||
| US201562132709P | 2015-03-13 | 2015-03-13 | |
| US62/132,709 | 2015-03-13 | ||
| EP15305830 | 2015-05-29 | ||
| EP15305830.0 | 2015-05-29 | ||
| PCT/US2015/040765 WO2016011260A1 (en) | 2014-07-16 | 2015-07-16 | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522316A JP2017522316A (ja) | 2017-08-10 |
| JP2017522316A5 true JP2017522316A5 (show.php) | 2018-08-23 |
| JP6912374B2 JP6912374B2 (ja) | 2021-08-04 |
Family
ID=53365943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502259A Active JP6912374B2 (ja) | 2014-07-16 | 2015-07-16 | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160137746A1 (show.php) |
| EP (2) | EP3753575A1 (show.php) |
| JP (1) | JP6912374B2 (show.php) |
| KR (3) | KR20230007538A (show.php) |
| CN (2) | CN114306592A (show.php) |
| AU (1) | AU2015289617B2 (show.php) |
| CA (1) | CA2955304C (show.php) |
| MX (2) | MX378872B (show.php) |
| PL (1) | PL3169362T3 (show.php) |
| RU (1) | RU2723018C2 (show.php) |
| WO (1) | WO2016011260A1 (show.php) |
| ZA (1) | ZA201700196B (show.php) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AU2012210481B2 (en) | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PH12014500342B1 (en) | 2011-09-16 | 2019-06-14 | Regeneron Pharma | METHODS FOR REDUCING LIPOPROTEIN (a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| TWI670077B (zh) | 2013-11-12 | 2019-09-01 | 賽諾菲生物技術公司 | 使用ｐｃｓｋ９抑制劑之給藥療程 |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| EP3197492A1 (en) * | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| TW201904608A (zh) * | 2017-06-09 | 2019-02-01 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| KR20200129127A (ko) * | 2018-03-06 | 2020-11-17 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도 |
| KR20220107210A (ko) * | 2019-11-18 | 2022-08-02 | 에이디 파마슈티컬스 컴퍼니 리미티드 | 항-pcsk9 항체 및 그의 용도 |
| WO2022032137A1 (en) * | 2020-08-07 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AU2012210481B2 (en) * | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| PH12014500342B1 (en) * | 2011-09-16 | 2019-06-14 | Regeneron Pharma | METHODS FOR REDUCING LIPOPROTEIN (a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| EA039310B1 (ru) * | 2015-02-26 | 2022-01-12 | Санофи Байотекнолоджи | Способы снижения сердечно-сосудистого риска |
-
2015
- 2015-07-16 RU RU2017104799A patent/RU2723018C2/ru active
- 2015-07-16 KR KR1020227045465A patent/KR20230007538A/ko not_active Ceased
- 2015-07-16 MX MX2017000628A patent/MX378872B/es unknown
- 2015-07-16 US US14/801,392 patent/US20160137746A1/en not_active Abandoned
- 2015-07-16 CN CN202111397525.XA patent/CN114306592A/zh active Pending
- 2015-07-16 JP JP2017502259A patent/JP6912374B2/ja active Active
- 2015-07-16 KR KR1020177004219A patent/KR102482375B1/ko active Active
- 2015-07-16 WO PCT/US2015/040765 patent/WO2016011260A1/en not_active Ceased
- 2015-07-16 PL PL15760317T patent/PL3169362T3/pl unknown
- 2015-07-16 EP EP20174278.0A patent/EP3753575A1/en not_active Withdrawn
- 2015-07-16 CN CN201580049703.6A patent/CN107106678A/zh active Pending
- 2015-07-16 CA CA2955304A patent/CA2955304C/en active Active
- 2015-07-16 AU AU2015289617A patent/AU2015289617B2/en active Active
- 2015-07-16 KR KR1020247028498A patent/KR20240132123A/ko not_active Ceased
- 2015-07-16 EP EP15760317.6A patent/EP3169362B1/en active Active
-
2017
- 2017-01-10 ZA ZA2017/00196A patent/ZA201700196B/en unknown
- 2017-01-13 MX MX2021000289A patent/MX2021000289A/es unknown
-
2019
- 2019-10-24 US US16/662,313 patent/US20200255544A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522316A5 (show.php) | ||
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2017528427A5 (show.php) | ||
| JP2016538277A5 (show.php) | ||
| JP2017031213A5 (show.php) | ||
| JP2017506626A5 (show.php) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| US20230406957A1 (en) | Dosing regimens for use with pcsk9 inhibitors | |
| US20220144969A1 (en) | Methods for reducing cardiovascular risk | |
| ES2914978T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| ES2773111T3 (es) | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) | |
| JP2013023499A5 (show.php) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016538248A5 (show.php) | ||
| JP7744190B2 (ja) | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 | |
| JP2022177142A5 (show.php) | ||
| JP2015187125A5 (show.php) | ||
| JP2019509988A5 (show.php) | ||
| JP2019514907A5 (show.php) | ||
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| Liu et al. | A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis | |
| KR20190014117A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| JP2014511361A5 (show.php) |